ClinicalTrials.gg
RecruitingNCT05098613Updated Jul 9, 2026

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

A Phase 1 interventional study of CD19x22 CAR T Cells in Non-Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma (B-NHL) and Mantle Cell Lymphoma (MCL), sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Primary conditionLymphoma, Mantle-CellRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Mantle-Cell
Why
  1. The study's listed conditions name Lymphoma, Mantle-Cell, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Colorado, Denver · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 905 studies in Lymphoma, Mantle-Cell with a site in United States — 81 open to participants now, 149 under way, 7 of them phase 3. Lymphoma, Mantle-Cell · United States.

Planned enrollment
178th of 777
68 · median 35
Started
2021
with 28 others
Phase 1
313 of 905
27 open now
Primary completion
2026-12
later than 43 of 148 live
Registered
818th of 905
by date

Among the 905 studies in Lymphoma, Mantle-Cell with a site in United States, this one is the 178th largest by planned enrollment of the 777 interventional ones that give a count, is one of 29 that started in 2021, is one of 313 in phase 1, reaches primary completion later than 43 of the 148 other live ones, and was the 818th registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

81 of the 905 studies in Lymphoma, Mantle-Cell with a site in United States are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Lymphoma, Mantle-Cell with a site in United States, or all of them as a file.
02

Study summary

This open-label, single arm phase 1 trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in adolescents and adults with relapsed/refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL). This trial will determine the maximum tolerated dose of CD19x22 CAR T cells using a standard 3+3 trial design.

Read the detailed description

To determine the safety and tolerability of infusing CD19x22 CAR T, generated using a bicistronic vector, in adolescents and adults with R/R B-NHL, and to determine the recommended Phase II dose (RP2D).

Secondary objectives for all subjects include: 1) Feasibility of manufacturing and infusion, 2) Safety of infusion and 3) Efficacy: Descriptive characterization of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) at Day +90. As well, progression-free survival (PFS), overall survival (OS), duration of remission (DOR) and overall response rate (ORR) will be determined at 1 year. Efficacy will be descriptively stratified based on prior receipt of CAR-T cell therapy.

03

Conditions studied

  • Non-Hodgkin Lymphoma
  • B-cell Non-Hodgkin Lymphoma (B-NHL)
  • Mantle Cell Lymphoma (MCL)
  • CNS Lymphoma

Browse trials for

Keywords

  • Relapsed
  • Refractory
04

In context

Lymphoma, Mantle-Cell Reclassified

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

This study's planned enrollment of 68 is above the median of 37 across 1,003 interventional studies indexed under Lymphoma, Mantle-Cell.

Browse Lymphoma, Mantle-Cell studies →

Lead sponsor

University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.

Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.

Compared within Lymphoma, Mantle-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: ≥ 16 years of age with no upper age limit. (NOTE: the first three subjects on this trial must be ≥ 18 years of age.)

COHORT 1: Non-CNS B-NHL

  1. confirmed aggressive B-cell NHL including the following types defined by World Health Organization (WHO) 2008:

    1. Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified; T cell/histiocyte rich large B cell lymphoma; DLBCL associated with chronic inflammation; Epstein Barr Virus (EBV)+ DLBCL of the elderly; OR
    2. Primary mediastinal (thymic) large B cell lymphoma; OR
    3. Transformation to DLBCL; OR
    4. High grade B-cell Lymphoma (HGBL).
  2. Subjects must not have any signs or symptoms of CNS disease or detectable evidence of CNS disease on magnetic resonance imaging (MRI) at screening; subjects who have been previously treated for CNS disease, but have no evidence of disease at screening are eligible for this cohort.
  3. Subjects must have disease progression confirmed by either flow cytometry or immunohistochemistry (IHC), disease stabilization, or disease recurrence after at least two .

    1. The two lines of prior therapy must include an anthracycline and anti-CD20 monoclonal antibody treatment.
    2. Relapse or after single antigen targeting CAR T cell therapy
  4. Must have evaluable or according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma; lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.

COHORT 2: MANTLE CELL LYMPHOMA (MCL)

  1. Mantle Cell Lymphoma (MCL).

    1. Results of all tests conducted on the tissue at initial diagnosis and/or relapse, including, but not limited to, the MCL subtype (classic and blastoid), Ki-67 proliferation index, and TP53 mutation status should be provided if done.
  2. Subjects must have relapsed and/or refractory MCL confirmed by either flow cytometry or immunohistochemistry (ICH), disease stabilization, or disease recurrence after at least two lines of therapy including any combination of the agents below:

    1. An anti-CD20-directed therapy
    2. A BTK inhibitor
    3. Anthracycline or Bendamustine
    4. Relapse or refractory after single antigen targeting CAR T cell therapy.
  3. Must have evaluable or measurable disease according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma; lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy. MCL patients without measurable nodal or extranodal disease by IWG criteria are eligible if they have bone marrow involvement of MCL at relapse

COHORT 3: PRIMARY CNS LYMPHOMA OR SECONDARY CNS LYMPHOMA

  1. Subjects with relapsed and/or refractory primary CNS lymphoma (PCNSL) OR secondary CNS lymphoma (SCNSL), as defined by the following:

    a. Absence of measurable disease outside the CNS, as determined by radiographic imaging (i.e. PET/CT).

    b. Detectable CNS disease, as defined as: i. At least 1 site of measurable disease within the brain or spinal cord that is ≥ 1 cm in the longest diameter based on MRI or PET/CT imaging; OR, ii. CSF-positive disease only (confirmed by presence of persistent disease, detected by cytology or flow cytometry) at the time of enrollment iii. Neoplastic B-cells detectable within the vitreous by flow cytometry or cytology

  2. Subjects must have disease progression confirmed by either flow cytometry or immunohistochemistry (IHC), disease stabilization, or disease recurrence after at least one line of therapy.

ALL COHORTS:

  1. Subjects who have undergone stem cell transplantation (SCT) with disease progression or relapse are eligible.
  2. Subjects who have undergone allogeneic SCT will be eligible if, in addition to meeting other eligibility criteria, are:

    1. At least 100 days post-transplant,
    2. Do not have active (GVHD)
  3. Any standard of care systemic therapy prior to leukapheresis must follow the .
  4. Any use (dexamethasone or prednisone) prior to apheresis must follow the washout period. Physiological replacement doses are allowable with no washout period. Topical or inhaled steroids for localized GVHD is allowable.
  5. Peripheral blood CD3 count must be >0.15 x 10 (to the 6th) cells/mL within 14 days prior to proceeding with apheresis.
  6. Toxicities from prior therapy must be stable and recovered to ≤ grade 1 (exceptions include non- toxicities such as alopecia and the organ function definitions provided in inclusion criteria 12).
  7. (ECOG) performance status of 0-2, or ≥ 80%.
  8. Adequate organ function as defined by:

    1. (ANC) ≥ 500/μL
    2. count ≥ 50,000/ μL.
    3. Renal: Creatinine ≤ 2 mg/dL OR (as estimated by Cockcroft Gault equation) ≥ 60 mL/min.
    4. Hepatic: Serum (ALT)/aspartate aminotransferase (AST) ≤ 3 (ULN).
    5. Total ≤ 2 mg/dl, except in subjects with Gilbert's syndrome where a bilirubin \<4.0 will be acceptable.
    6. Cardiac: ≥ 40%, no evidence of physiologically significant pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant (ECG) findings within 6 weeks of apheresis.
    7. Pulmonary: No clinically significant pleural effusion and;

    i. Baseline oxygen saturation must be > 92% on room air

  9. Females of must have a negative serum pregnancy test (females who have undergone surgical sterilization or who have been for at least 6 months are not considered to be of childbearing potential).
  10. Subjects of childbearing or child-fathering potential must be willing to practice from the time of enrollment on this study and for 12 months after receiving the CD19x22 infusion; females of childbearing potential must have a negative pregnancy test.

21. Must be able to give ; subjects unable to give informed consent will not be eligible for this study.

22. Be able to consent to long-term follow-up protocol (#20-0188).

Exclusion criteria

Exclusion Criteria:

  1. Age \< 16 years of age.
  2. Patients who are intolerant of contrast-enhanced MRI due to allergic reactions to contrast agents. Only applicable to Cohort 3.
  3. Patients with active, poorly controlled hydrocephalus defined as increase/worsening in symptoms (headaches, nausea/vomiting, lethargy, or neurological function with increased hydrocephalus noted on radiologic evaluation and/or need for CSF diversion. Note: If hydrocephalus is controlled after CSF diversion, patient may be eligible for the study. Only applicable to Cohort 3.
  4. Patients with brainstem lesions. Only applicable to Cohort 3.
  5. History of other , unless they have been disease free for at least 3 years. Exceptions include non-melanoma skin cancer or carcinoma in situ and localized prostate cancer not on active treatment.
  6. Uncontrolled fungal, bacterial, viral, or other infection requiring antimicrobials for management; uncomplicated infections are permitted if responding to active treatment.
  7. Known history of infection with (HIV) or (hepatitis B surface antigen [HBsAg] positive) or .
  8. History of known myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other cardiac disease within 12 months of enrollment or have cardiac atrial or cardiac ventricular lymphoma involvement.
  9. Venous thrombosis or embolism not managed on a stable regimen of anticoagulation.
  10. Any medical condition that in the judgement of the sponsor is likely to interfere with assessment of safety or efficacy of study treatment.
  11. History of severe immediate reaction to any of the agents used in this study.
  12. Pregnancy (serum pregnancy test must be obtained at time of enrollment for females of and to be repeated 72 hours prior to lymphodepleting chemotherapy regimen); females who have undergone surgical sterilization or who have been for at least 6 months are not considered to be childbearing potential.
  13. Lactating.
  14. In the investigator's judgment, the subject is unlikely to complete all protocol required study visits or procedures, including follow up visits, or comply with the study requirements for participation.
  15. Unwilling to participate in long-term follow-up protocol that is required if CAR T cell therapy is administered at CU Anschutz.

APHERESIS ELIGIBILITY

In order to proceed with apheresis, enrolled participants cannot have active, severe infection. For the purpose of this trial, active, severe infection is defined as:

  • Positive blood culture within 48 hours of the start of the apheresis procedure, OR
  • Fever >38.2°C AND clinical signs of infection within 48 hours of start of apheresis procedure

Additionally, participants should have the following labs within 14 days of apheresis:

  • CBC with manual differential
  • Lymphocyte enumeration (TBNK) panel to measure CD3 count

    • CD3 count must be >0.15 x 106 cells/mL

LYMPHODEPLETING CHEMOTHERAPY ELIGIILITY:

In order to proceed with lymphodepleting chemotherapy, enrolled participants must meet all eligibility criteria below within 72 hours prior to lymphodepletion, unless otherwise specified:

  • If the participant received bridging therapy after apheresis, confirmation of disease reevaluation is required. It must be within 6 weeks of initiation of LD chemotherapy.

    • Confirmation that the participant has met the for bridging therapy.
  • Negative serum pregnancy test (for women of childbearing potential)
  • Adequate organ function as defined by:

    • (ANC) ≥ 500/μL.
    • count ≥ 50,000/ μL.
    • Renal: Creatinine ≤ 2 mg/dL OR (as estimated by Cockcroft Gault equation) ≥ 60 mL/min.
    • Hepatic: Serum (ALT)/aspartate aminotransferase (AST) ≤ 3 (ULN).
    • Total ≤ 2 mg/dl, except in subjects with Gilbert's syndrome where a bilirubin \<3.0 will be acceptable.
    • Pulmonary: No clinically significant pleural effusion and; Baseline oxygen saturation must be > 92% on room air.
    • Cardiac: ≥ 45%, no evidence of physiologically significant pericardial effusion as determined by an echocardiogram (ECHO) (only if subject received bridging anthracycline or developed a significant illness prior to LD-chemo per investigator assessment.) If clinically indicated, ECHO must be performed within 2 weeks prior to LD-chemotherapy.
  • Cohort 3 patients ONLY:

    • Patients must not have -dependent CNS lymphoma, defined as requiring more than 1 mg/kg/day or prednisone or equivalent within 14 days prior to the start of LD chemotherapy.
    • Patients may not have poorly controlled hydrocephalus prior to the initiation of LD chemotherapy.

CD19x22 CAR T CELL INFUSION ELIGIBILITY

In order to proceed with CD19x22 CAR T Cell Infusion, enrolled participants must meet all eligibility criteria below within 24 hours prior to CD19x22 CAR T Cell infusion, unless otherwise specified:

  • CD19x22 CAR T cells must have met manufacturing release criteria (unless prospectively approved by IND Sponsor, Gates Institute Medical Lead, and FDA).
  • Confirmation that the site has Anakinra and Ruxolitinib in stock and available (should IEC-HS treatment be required).
  • ≤2 or ≥ 50%.
  • Clinically stable without evidence of vital sign instability, including the lack of supportive vasoactive drugs or intensive care unit support.
  • Oxygen saturation > 92% on room air; cannot be on supplemental oxygen.
  • No evidence of uncontrolled, significant tumor lysis syndrome prior to cell infusion per investigator assessment.
  • No evidence of rapidly progressive NHL per investigator determination.
  • Participants' temperature is \<38.0 °C within 48 hours prior to cell infusion. (If the source of fever cannot be identified [after thorough infectious disease work-up], and the suspected cause is underlying malignancy, discussion and approval by the Gates Institute Medical Lead may allow continued infusion of CD19x22 cells. This should be appropriately documented in the patient's medical record.
  • Liver transaminase (ALT and AST) \< 5 x institutional ULN (\< grade 3) based on age- and laboratory- specific normal ranges.
  • Adequate renal function as defined by creatinine ≤ 2 mg/dL OR creatinine clearance (as estimated by the Cockcroft- Gault equation) ≥ 60 mL/min.

If these criteria are not met, measures can be taken to resolve the underlying condition(s). If successful, cells may be infused up to (and including) 7 days following the time of the planned infusion with no additional lymphodepletion. If the CD19x22 CAR T Cell infusion is delayed more than 7 days, lymphodepleting chemotherapy MAY be repeated, per the investigator's discretion. Prior to commencing a second round of lymphodepletion, participants must meet lymphodepletion criteria described above.

Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Cohort 1 Relapsed/Refractory Non-CNS B-Cell Non Hodgkin Lymphoma

    Lymphodepleting chemotherapy followed by infusion of CD19x22 CAR T Cells starting at dose level 1.

    Drug: CD19x22 CAR T Cells

  • Experimental
    Cohort 2 Relapsed/Refractory Mantle Cell Lymphoma

    Lymphodepleting chemotherapy followed by CD19x22 CART Infusion starting at dose level 2.

    Drug: CD19x22 CAR T Cells

  • Experimental
    Cohort 3: Relapsed and/or Refractory Primary CNS Lymphoma OR secondary CNS Lymphoma

    Lymphodepleting chemotherapy followed by CD19x22 CAR T Infusion starting at dose level 2

    Drug: CD19x22 CAR T Cells

Interventions

  • DrugCD19x22 CAR T Cells

    Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.

07

What researchers measure

Primary outcomes

  1. Overall safety and tolerability of CD19x22 CAR T Therapy in CAR-naive and CAR-treated subjects

    Assessed by Type, Frequency, and Severity of Adverse Events (AEs). All AEs, including laboratory abnormalities, will be graded using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grading criteria.

    Time frame: 12 Months Post Infusion

  2. Determine the Recommended Phase II Dose (RP2D) Level

    Incidence and frequency of Grade 3-5 toxicity occurring within the dose limiting toxicity (DLT) period post CD19x22 CAR T infusion. Grades 3-5 adverse events (AEs) are defined as Severe, Life-Threatening, and Fatal.

    Time frame: 30 Days Post Infusion

Secondary outcomes

  1. Feasibility of Manufacturing CD19x22 CAR T

    The feasibility of manufacturing the desired dose of anti-CD19x22 CAR T cells will be established using the percentage of patients for whom the desired dose of CAR T cells was successfully produced.

    Time frame: Day 0 (Infusion)

  2. Evaluate Safety of Infusion

    Percentage of study participants who receive CD19x22 CAR T infusion without infusion reaction

    Time frame: 30 Days Post Infusion

  3. Evaluate Clinical Efficacy of CD19x22 CAR T

    Clinical efficacy is defined through Lugano response criteria at Day +60 (Cohort 2 only), Day +90, 6 months, and 1 year. Efficacy will be stratified based on prior receipt of CAR T cell therapy.

    Time frame: 12 Months Post Infusion

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.

Of 73 non-industry phase 1 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 98. This study's planned 60 months is close to that.

Counting every sponsor, half of 128 studies reached it within 61 months; a quarter within 36 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2021
First posted
Oct 28, 2021
StartActual
Dec 21, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05098613
Responsible party
Sponsor
First posted
Oct 28, 2021
Start date
Dec 21, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 9, 2026

Study contacts

Derek Schatz
Contact
derek.schatz@cuanschutz.edu
7208480628
Manali Kamdar, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion